Cohen MS, Nirula A, Mulligan MJ, et al. - Researchers investigated the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities with high risk of SARS-CoV-2 exposure. In this randomized, double-blind, single-dose, phase 3 trial, 966 participants were included who were residents and staff of 74 skilled nursing and assisted living facilities in the United States with at least 1 confirmed SARS-CoV-2 index case and who were negative at baseline for SARS-CoV-2 infection and serology. COVID-19 infection was incident at 8.5% vs 15.2%, among those treated with bamlanivimab vs placebo, respectively, a difference that was statistically significant. This suggested reduced risk of COVID-19 in residents and staff of skilled nursing and assisted living facilities in correlation with receiving bamlanivimab monotherapy vs placebo.